TNFRSF11A and cancer: One review article showed that certain key factors, osteoprotegerin (OPG)/ receptor activator of NF-κB ligand (RANKL)/receptor activator of NF-κB (RANK), underlie the molecular mechanism of osteoclastogenesis [22], and the anti-human RANKL monoclonal antibody has been successfully applied to the treatment of osteoporosis and cancer-related bone disorders [23,24].